97282 • Pain Management Pearls: Opioids and Culture

Table of Contents

97282 • Pain Management Pearls: Opioids and Culture

How to Receive Credit

Course Overview

Audience

Accreditations & Approvals

Designations of Credit

Individual State Nursing Approvals

Special Approvals

Course Objective

Learning Objectives

Faculty

Faculty Disclosure

Division Planners

Division Planners Disclosure

Director of Development and Academic Affairs

Director Disclosure Statement

About the Sponsor

Disclosure Statement

Implicit Bias in Health Care

1. INTRODUCTION

2. OPIOID MANAGEMENT OF CHRONIC PAIN

INFORMED CONSENT AND TREATMENT AGREEMENTS

INITIATING A TRIAL OF OPIOID THERAPY

PERIODIC REVIEW AND MONITORING

PATIENT AND CAREGIVER EDUCATION

CONSULTATION AND REFERRAL

MEDICAL RECORDS

DISCONTINUING OPIOID THERAPY

3. THE IMPACT OF CULTURE ON PAIN AND PAIN MANAGEMENT

FACTORS THAT CONTRIBUTE TO RACIAL AND ETHNIC DISPARITIES IN PAIN MANAGEMENT

ALTERNATIVE REMEDIES

END-OF-LIFE CONSIDERATIONS

4. CONCLUSION

Works Cited

Evidence-Based Practice Recommendations Citations

97282 • Pain Management Pearls: Opioids and Culture

Alice Yick Flanagan, PhD, MSW

Mark Rose, BS, MA, LP

www.netce.com

Copyright © 2026 NetCE, All rights reserved.

Pain affects all domains of life, and clinicians have few effective tools at their disposal to help these patients. Opioids remain the strongest group of analgesic drugs available. Millions of patients are safely and effectively maintained on relatively high-dose opioids for chronic, severe pain and require these medications to function. However, opioids, like many medications, have serious risks and should not be treated like a cure-all. This dichotomy has resulted in many patients for whom opioid analgesics are appropriate increasingly experiencing barriers to pain relief. At greatest risk of unrelieved pain from stigma and bias are children, the elderly, racial and ethnic minorities, active duty or military veterans, and those with cancer, HIV, or sickle cell disease. Pain undertreatment in African American patients is especially widespread. As a result, prescribers, dispensers, and administrators would benefit from considering both the tenets of appropriate opioid prescribing and the impact of culture on experiences of pain and effective pain management.

97282 • Pain Management Pearls: Opioids and Culture

Education Category. Ethics - Human Rights

Release Date. 08/01/2026

Expiration Date. 07/31/2029

How to Receive Credit

To complete this course for continuing education credit please go to http://www.netce.com/course/3610 in your browser.

For assistance with receiving continuing education credit, please contact us at help@netce.com.

Course Overview

Pain affects all domains of life, and clinicians have few effective tools at their disposal to help these patients. Opioids remain the strongest group of analgesic drugs available. Millions of patients are safely and effectively maintained on relatively high-dose opioids for chronic, severe pain and require these medications to function. However, opioids, like many medications, have serious risks and should not be treated like a cure-all. This dichotomy has resulted in many patients for whom opioid analgesics are appropriate increasingly experiencing barriers to pain relief. At greatest risk of unrelieved pain from stigma and bias are children, the elderly, racial and ethnic minorities, active duty or military veterans, and those with cancer, HIV, or sickle cell disease. Pain undertreatment in African American patients is especially widespread. As a result, prescribers, dispensers, and administrators would benefit from considering both the tenets of appropriate opioid prescribing and the impact of culture on experiences of pain and effective pain management.

Audience

This course is designed for physicians, nurses, and allied health professionals who may intervene to improve the treatment of pain in diverse patient populations.

Accreditations & Approvals

In support of improving patient care, TRC Healthcare/NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NetCE is accredited by the International Accreditors for Continuing Education and Training (IACET). NetCE complies with the ANSI/IACET Standard, which is recognized internationally as a standard of excellence in instructional practices. As a result of this accreditation, NetCE is authorized to issue the IACET CEU.

Designations of Credit

This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credit(s) for learning and change. NetCE designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NetCE designates this continuing education activity for 2 ANCC contact hour(s). NetCE designates this continuing education activity for 1 pharmacotherapeutic/pharmacology contact hour(s). NetCE designates this continuing education activity for 2.4 hours for Alabama nurses. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Completion of this course constitutes permission to share the completion data with ACCME. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. This activity has been approved for the American Board of Anesthesiology’s® (ABA) requirements for Part II: Lifelong Learning and Self-Assessment of the American Board of Anesthesiology’s (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements. Maintenance of Certification in Anesthesiology Program® and MOCA® are registered certification marks of the American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®. Successful completion of this CME activity, which includes participation in the activity with individual assessments of the participant and feedback to the participant, enables the participant to earn 2 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit. This activity has been designated for 2 Lifelong Learning (Part II) credits for the American Board of Pathology Continuing Certification Program. Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program. AACN Synergy CERP Category A. NetCE is authorized by IACET to offer 0.2 CEU(s) for this program.

Individual State Nursing Approvals

In addition to states that accept ANCC, NetCE is approved as a provider of continuing education in nursing by: Alabama, Provider #ABNP0353 (valid through July 30, 2029); Arkansas, Provider #50-2405; California, BRN Provider #CEP9784; California, LVN Provider #V10662; California, PT Provider #V10842; District of Columbia, Provider #50-2405; Florida, Provider #50-2405; Georgia, Provider #50-2405; Kentucky, Provider #7-0054 through 12/31/2027; South Carolina, Provider #50-2405; West Virginia RN and APRN, Provider #50-2405.

Special Approvals

This course meets the Michigan requirement for 2 hours of continuing education in pain and pain symptom management. This course meets 2 of the Alabama requirement for controlled substance education for those who hold a Qualified Alabama Controlled Substance Certificate. This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.

Course Objective

The purpose of this course is to increase clinicians' knowledge and awareness of the appropriate prescription of opioids and the impact of culture on issues of pain and pain management in order to improve the provision of care and patients' quality of life.

Learning Objectives

Upon completion of this course, you should be able to:

1. Discuss characteristics of appropriate and inappropriate opioid prescribing and contributory factors to both.

2. Outline the appropriate periodic review and monitoring of patients prescribed opioid analgesics.

3. Describe necessary components of patient/caregiver education for prescribed opioid analgesics, including guidance on the safe use and disposal of medications.

4. Analyze how culture, race and ethnicity influence how pain is defined, expressed, and experienced.

Faculty

Mark Rose, BS, MA, LP, is a licensed psychologist in the State of Minnesota with a private consulting practice and a medical research analyst with a biomedical communications firm. Earlier healthcare technology assessment work led to medical device and pharmaceutical sector experience in new product development involving cancer ablative devices and pain therapeutics. Along with substantial experience in addiction research, Mr. Rose has contributed to the authorship of numerous papers on CNS, oncology, and other medical disorders. He is the lead author of papers published in peer-reviewed addiction, psychiatry, and pain medicine journals and has written books on prescription opioids and alcoholism published by the Hazelden Foundation. He also serves as an Expert Advisor and Expert Witness to law firms that represent disability claimants or criminal defendants on cases related to chronic pain, psychiatric/substance use disorders, and acute pharmacologic/toxicologic effects. Mr. Rose is on the Board of Directors of the Minneapolis-based International Institute of Anti-Aging Medicine and is a member of several professional organizations.

Alice Yick Flanagan, PhD, MSW, received her Master’s in Social Work from Columbia University, School of Social Work. She has clinical experience in mental health in correctional settings, psychiatric hospitals, and community health centers. In 1997, she received her PhD from UCLA, School of Public Policy and Social Research. Dr. Yick Flanagan completed a year-long post-doctoral fellowship at Hunter College, School of Social Work in 1999. In that year she taught the course Research Methods and Violence Against Women to Masters degree students, as well as conducting qualitative research studies on death and dying in Chinese American families.

Previously acting as a faculty member at Capella University and Northcentral University, Dr. Yick Flanagan is currently a contributing faculty member at Walden University, School of Social Work, and a dissertation chair at Grand Canyon University, College of Doctoral Studies, working with Industrial Organizational Psychology doctoral students. She also serves as a consultant/subject matter expert for the New York City Board of Education and publishing companies for online curriculum development, developing practice MCAT questions in the area of psychology and sociology. Her research focus is on the area of culture and mental health in ethnic minority communities.

Faculty Disclosure

Contributing faculty, Mark Rose, BS, MA, LP, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Contributing faculty, Alice Yick Flanagan, PhD, MSW, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Division Planners

John M. Leonard, MD

Mary Franks, MSN, APRN, FNP-C

Division Planners Disclosure

The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Director of Development and Academic Affairs

Sarah Campbell

Director Disclosure Statement

The Director of Development and Academic Affairs has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

About the Sponsor

The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.

Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.

Disclosure Statement

It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.

Implicit Bias in Health Care

The role of implicit biases on healthcare outcomes has become a concern, as there is some evidence that implicit biases contribute to health disparities, professionals' attitudes toward and interactions with patients, quality of care, diagnoses, and treatment decisions. This may produce differences in help-seeking, diagnoses, and ultimately treatments and interventions. Implicit biases may also unwittingly produce professional behaviors, attitudes, and interactions that reduce patients' trust and comfort with their provider, leading to earlier termination of visits and/or reduced adherence and follow-up. Disadvantaged groups are marginalized in the healthcare system and vulnerable on multiple levels; health professionals' implicit biases can further exacerbate these existing disadvantages.

Interventions or strategies designed to reduce implicit bias may be categorized as change-based or control-based. Change-based interventions focus on reducing or changing cognitive associations underlying implicit biases. These interventions might include challenging stereotypes. Conversely, control-based interventions involve reducing the effects of the implicit bias on the individual's behaviors. These strategies include increasing awareness of biased thoughts and responses. The two types of interventions are not mutually exclusive and may be used synergistically.

1. INTRODUCTION

Pain affects all domains of life, and clinicians have few effective tools at their disposal to help these patients [1]. Opioids remain the strongest group of analgesic drugs available [2]. Millions of patients are safely and effectively maintained on relatively high-dose opioids for chronic, severe pain and require these medications to function. Public pressure and the mischaracterization of patients as "drug addicts" has increasingly deterred prescribers from treating patients with chronic pain, successfully managed with opioids for years or decades, rather than improving safety practices [3,4]. However, opioids, like many medications, have serious risks and should not be treated like a cure-all [5]. This dichotomy has resulted in many patients, for whom opioid analgesics are appropriate, increasingly experiencing barriers to pain relief.

Misunderstanding and misapplication of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain, in part, led to lawmakers and health systems toward revoking, restricting, or denying access to opioid medications, in some cases for individuals who relied on them (e.g., those with chronic pain) or those for whom the guideline was not intended (patients with cancer or at the end of life) [54]. The CDC acknowledged that their guidance may have fueled the restrictions and led to needless suffering. The updated 2022 CDC guideline emphasizes that patients need not fail a trial of non-opioid analgesics before opioids are prescribed and that the decision to prescribe, adjust, or discontinue opioids should be based primarily on clinical indication, judgement, and shared decision-making.

The 2022 CDC guideline also notes that opioids have historically been inaccessible to many patients because of factors such as inadequate clinician education, training, and guidance; unconscious bias; a shortage of pain management specialists; insufficient access to treatment modalities such as behavioral therapy; siloed health systems; insurance coverage and reimbursement policies; and lack of clarity about the evidence supporting different pain treatments [54]. At greatest risk of unrelieved pain from stigma and bias are children, women, the elderly, racial and ethnic minorities, persons with cognitive impairment, active duty or military veterans, and those with cancer, HIV, or sickle cell disease [54]. Individuals at the end of life are also at risk for inadequate pain treatment. Pain undertreatment in Black and Hispanic patients is especially widespread, from prevalent misperceptions that these groups have a higher pain tolerance [6,54]. As a result, prescribers, dispensers, and administrators would benefit from considering both the tenets of appropriate opioid prescribing and the impact of culture on experiences of pain and effective pain management.

2. OPIOID MANAGEMENT OF CHRONIC PAIN

Evidence Based Practice Recommendation

The Centers for Disease Control and Prevention recommends that clinicians should maximize use of nonpharmacologic and nonopioid pharmacologic therapies as appropriate for the specific condition and patient and only consider initiating opioid therapy if expected benefits for pain and function are anticipated to outweigh risks to the patient.

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm

Last Accessed: July 24, 2026

Level of Evidence: Expert Opinion/Consensus Statement

All patients with pain have a level of risk that can only be roughly estimated initially and modified over time as more information is obtained. There are several essential steps of opioid prescribing for chronic pain to help mitigate any potential problems [7,54]:

- Diagnosis with an appropriate differential

- Psychologic assessment, including risk of substance use disorders

- Review of patient history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data (when available)

- Informed consent

- Treatment agreement

- Pre- and post-treatment assessments of pain level and function

- Appropriate trial of opioid therapy with or without adjunctive medication

- Reassessment of patient levels of pain and functioning

- Regular assessment with the 5 A's (i.e., analgesia, activity, adverse effects, aberrant behaviors, and affect)

- Periodically review pain diagnosis, comorbid conditions (including substance use disorders), and state PDMP data (when available)

- Documentation

In addition to federal regulations, most states have established laws and rules governing the prescribing and dispensing of opioid analgesics. It is each prescriber's responsibility to have knowledge of and adhere to the laws and rules of the state in which they prescribe.

INFORMED CONSENT AND TREATMENT AGREEMENTS

The initial opioid prescription is preceded by a written informed consent or "treatment agreement" [8]. This agreement should address potential side effects, tolerance and/or physical dependence, drug interactions, motor skill impairment, limited evidence of long-term benefit, misuse, dependence, addiction, and overdose. Informed consent documents should include information regarding the risk/benefit profile for the drug(s) being prescribed. The prescribing policies should be clearly delineated, including the number/frequency of refills, early refills, and procedures for lost or stolen medications.

The treatment agreement also outlines joint prescriber and patient responsibilities. The patient agrees to using medications safely, only obtaining opioids from one clinician or practice, and consenting to routine urine drug tests (UDTs). The prescriber's responsibility is to address unforeseen problems and prescribe scheduled refills. Reasons for opioid therapy change or discontinuation should be listed. Agreements can also include sections related to follow-up visits, monitoring, and safe storage and disposal of unused drugs.

It is important to remember that treatment agreements are only one aspect of developing a safe opioid use plan. The evidence to support the use of such agreements to decrease the misuse of opioids is relatively weak, with little or no proof of improvements in adherence or patient care [9].

INITIATING A TRIAL OF OPIOID THERAPY

Opioid therapy should be presented as a trial for a pre-defined period (e.g., ≤30 days). As noted, the goals of treatment should be reasonable improvements in pain, function, depression, anxiety, and avoidance of unnecessary or excessive medication use [8]. The treatment plan should describe therapy selection, measures of progress, and other diagnostic evaluations, consultations, referrals, and therapies.

In opioid-naïve patients, start at the lowest possible dose and titrate to effect. Dosages for opioid-tolerant patients should always be individualized and titrated by efficacy and tolerability. The need for frequent progress and benefit/risk assessments during the trial should be included in patient education. Patients should also have full knowledge of the warning signs and symptoms of respiratory depression.

Prescribers should be knowledgeable of federal and state opioid prescribing regulations. Issues of equianalgesic dosing, close patient monitoring during all dose changes, and cross-tolerance with opioid conversion should be considered. If necessary, treatment may be augmented, with preference for nonopioid and immediate-release opioids over extended-release/long-acting (ER/LA) opioid formulations. Taper opioid dose when no longer needed [10].

PERIODIC REVIEW AND MONITORING

When implementing a chronic pain treatment plan that involves the use of opioids, the patient should be frequently reassessed for changes in pain origin, health, and function [8]. This can include input from family members and/or the state PDMP. These state programs are one of the most effective measures for reducing opioid analgesic diversion and abuse, but their efficacy is undermined by inconsistent use [9]. During the initiation phase and during any changes to the dosage or agent used, patient contact should be increased. Decisions regarding the continuation, modification, or termination of opioid therapy for pain should be based on evaluation of the patient's progress and the absence of substantial risks or adverse events [8]. At every visit, chronic opioid response may be monitored according to the 5 A's [11]:

- Analgesia

- Activities of daily living

- Adverse effects

- Aberrant drug-related behaviors

- Affect (i.e., patient mood)

Assessment During Ongoing Opioid Therapy

Signs and symptoms that, if present, may suggest a problematic response to the opioid and interference with the goal of functional improvement include [11]:

- Excessive sleeping or days and nights turned around

- Diminished appetite

- Inability to concentrate or short attention span

- Mood volatility, especially irritability

- Lack of involvement with others

- Impaired functioning due to drug effects

- Use of the opioid to regress instead of re-engaging in life

- Lack of attention to hygiene and appearance

- Escalation of pain and/or pain medication dose

- Continual dose escalation

- Increasing number of medications prescribed to treat the side effects of opioids

Patients who display any of these signs or symptoms should be assessed for potential opioid misuse or use disorder/addiction. Persons in active addiction should be referred to an addiction and/or pain specialist.

The decision to continue, change, or terminate opioid therapy is based on progress toward treatment objectives and absence of adverse effects and risks of overdose or diversion [8]. Satisfactory therapy is indicated by improvements in pain, function, and quality of life. Brief assessment tools to assess pain and function may be useful, as may UDTs. Treatment plans may include periodic pill counts to confirm adherence and minimize diversion.

Information obtained by patient history, physical examination, and interview, from family members, a spouse, or state prescription drug monitoring database, and from the use of screening and assessment tools can help the clinician to stratify the patient according to level of risk for developing problematic opioid behavioral responses. A urine drug test should be performed prior to initiating opioid treatment.

Low-risk patients receive the standard level of monitoring, vigilance, and care. Moderate-risk patients should be considered for an additional level of monitoring and provider contact, and high-risk patients are likely to require intensive and structured monitoring and follow-up contact, additional consultation with psychiatric and addiction medicine specialists, and limited supplies of short-acting opioid formulations.

If substance abuse is active, in remission, or in the patient's history, one should consult an addiction specialist before starting opioids. In the setting of active substance abuse, opioids should not be prescribed until the patient is engaged in a treatment/recovery program or other arrangement are made, such as addiction professional co-management and additional monitoring. When considering an opioid analgesic (particularly those that are extended-release or long-acting), one must always weigh the benefits against the risks of overdose, abuse, addiction, physical dependence and tolerance, adverse drug interactions, and accidental exposure by children.

PATIENT AND CAREGIVER EDUCATION

Safe Use of Opioids

Patients and caregivers should be counseled regarding the safe use and disposal of opioids. As part of its mandatory Risk Evaluation and Mitigation Strategy (REMS) for ER/LA opioids, the U.S. Food and Drug Administration (FDA) has developed a patient counseling document with information on the patient's specific medications, instructions for emergency situations and incomplete pain control, and warnings not to share medications or take them unless prescribed [10]. A copy of this form may be accessed online at https://www.fda.gov/media/114694/download.

When prescribing opioids, clinicians should provide patients with the following information and instructions [10]:

- Product-specific information

- Taking the opioid as prescribed

- Importance of dosing regimen adherence, managing missed doses, and prescriber contact if pain is not controlled

- Warning and rationale to never break or chew/crush tablets or cut or tear patches prior to use

- Warning and rationale to avoid other central nervous system depressants, such as sedative-hypnotics, anxiolytics, alcohol, or illicit drugs

- Warning not to abruptly halt or reduce the opioid without physician oversight of safe tapering when discontinuing

- The potential of serious side effects or death

- Risk factors, signs, and symptoms of overdose and opioid-induced respiratory depression, gastrointestinal obstruction, and allergic reactions

- The risks of falls, using heavy machinery, and driving

- Warning and rationale to never share an opioid analgesic

- Rationale for secure opioid storage

- Warning to protect opioids from theft

- Instructions for disposal of unneeded opioids, based on product-specific disposal information

It is now recommended or required (in some jurisdictions) that an opioid antagonist (naloxone) is offered when prescribing opioids, particularly to patients at increased risk for overdose (e.g., patients with a history of overdose or substance use disorder, patients taking benzodiazepines with opioids, patients at risk for returning to a high dose to which they have lost tolerance, and patients taking higher dosages of opioids [≥50 MME/day]) [54]. Education on overdose prevention and opioid agonist use should be provided to patients receiving naloxone prescriptions and to members of their households or other caregivers.

Disposal of Opioids

There are no universal recommendations for the proper disposal of unused opioids, and patients are rarely advised of what to do with unused or expired medications. According to the Office of National Drug Control Policy, most medications that are no longer necessary or have expired should be returned to a pharmacy or other drug take-back location; alternately, they can be removed from their containers, mixed with undesirable substances (e.g., cat litter, used coffee grounds), and put into an impermeable, nondescript container (e.g., disposable container with a lid or a sealed bag) before throwing in the trash [12]. The FDA states that most opioid medications, including oxycodone/acetaminophen (Percocet), oxycodone (OxyContin tablets), and transdermal fentanyl (Duragesic Transdermal System), can be flushed down the toilet instead of thrown in the trash if a take-back option is not feasible [13]. Disposal by flushing down the toilet provides immediate and definitive elimination of safety hazards from intentional use or accidental exposure involving opioid products. All transdermal patch opioid products should be flushed down the toilet after folding in half by adhesive side against adhesive side [13]. The FDA provides a free toolkit of materials (e.g., social media images, fact sheets, posters) to raise awareness of the serious dangers of keeping unused opioid pain medicines in the home and with information about safe disposal of these medicines. The Remove the Risk Outreach toolkit is updated regularly and can be found at https://www.fda.gov/drugs/ensuring-safe-use-medicine/safe-opioid-disposal-remove-risk-outreach-toolkit [14]. Patients should be advised to flush prescription drugs down the toilet only if the label or accompanying patient information specifically instructs doing so.

The American Society of Health-System Pharmacists has established best practices to avoid diversion of unused drugs and educate patients regarding drug disposal [15]:

- Consider writing prescriptions in smaller amounts

- Educate patients about the safe use of opioids, including not sharing prescriptions with others.

- Give drug-specific information to patients about the temperature at which they should store their medications. Generally, the bathroom is not the best storage place. It is damp and moist, potentially resulting in potency decrements, and accessible to many people, including children and teens, resulting in potential theft or safety issues. Remind patients that medications should be stored out of reach of children and in a safe place—preferably locked— to prevent other family members and visitors from taking them.

- Talk to patients about the most appropriate way to dispose of expired, unwanted, and unused medications. The preferred option is that unwanted or unused pills, liquids or other medications should be disposed of in a local "take-back" or mail-back program or medication drop box at a police station, pharmacy, or authorized collection site.

The FDA recommends that patients type "drug disposal" or "medication disposal" into Google or other map app to check for local take-back options, which typically return results for all pharmacies in the area. Patients may also visit https://apps.deadiversion.usdoj.gov/pubdispsearch/spring/main?execution=e1s1 to locate nearby drug take-back locations, including pharmacies [53].

CONSULTATION AND REFERRAL

It is important to seek consultation or patient referral when input or care from a pain, psychiatry, addiction, or mental health specialist is necessary. Clinicians who prescribe opioids should become familiar with opioid addiction treatment options (including licensed opioid treatment programs for methadone and office-based opioid treatment for buprenorphine) if referral is needed [8].

Ideally, providers should be able to refer patients with active substance abuse who require pain treatment to an addiction professional or specialized program. In reality, these specialized resources are scarce or non-existent in many areas [8]. Therefore, each provider will need to decide whether the risks of continuing opioid treatment while a patient is using illicit drugs outweigh the benefits to the patient in terms of pain control and improved function [16].

MEDICAL RECORDS

Documentation is a necessary aspect of all patient care, but it is of particular importance when opioid prescribing is involved. All clinicians should maintain accurate, complete, and up-to-date medical records, including all written or telephoned prescription orders for opioid analgesics and other controlled substances, all written instructions to the patient for medication use, and the name, telephone number, and address of the patient's pharmacy [8]. Good medical records demonstrate that a service was provided to the patient and that the service was medically necessary. Regardless of the treatment outcome, thorough medical records protect the prescriber. Remember that if an AI scribe is used to write medical records, it is the clinician's responsibility to ensure accuracy of the document.

DISCONTINUING OPIOID THERAPY

The decision to continue or end opioid prescribing should be based on a joint discussion of the anticipated benefits and risks. An opioid should be discontinued with resolution of the pain condition, intolerable side effects, inadequate analgesia, lack of improvement in quality of life despite dose titration, deteriorating function, or significant aberrant medication use [8]. The results of a toxicology test should not be grounds for immediate dismissal or opioid discontinuation [54]. The CDC guideline states that dismissal could have adverse consequences for patient safety, potentially including the patient obtaining opioids or other drugs from alternative sources and the clinician missing opportunities to facilitate treatment for substance use disorder [54].

Clinicians should provide physically dependent patients with a safely structured tapering protocol. Withdrawal is managed by the prescribing physician or referral to an addiction specialist. Patients should be reassured that opioid discontinuation is not the end of treatment; continuation of pain management will be undertaken with other modalities through direct care or referral.

3. THE IMPACT OF CULTURE ON PAIN AND PAIN MANAGEMENT

Patients' experiences of pain may be frustrating if they defy biomedical explanation, and the treatment of pain tends to be stigmatized [17]. When culture, race, and ethnicity are taken into consideration, the treatment of pain becomes even more complex. Practitioners should address how patients construct the meaning and experiences of pain rather than simply dealing with a set of medical procedures and routines [17].

Practitioners working with patients experiencing pain should be aware of the patient's cultural value and belief systems and how they impact their pain experience and also how their own cultural background and professional culture/system affects how they view pain. Furthermore, culture can influence access to and utilization of pain management services and medications and provider communication [22]. For the most part, practitioners are trained and socialized from a biomedical tradition [23]. Practitioners should reflect on their own experiences and the values and beliefs they attribute to pain [24]. Take a moment to consider the following self-reflective questions [24].

Pain Experiences in Childhood

- When you were a child, how did those who cared for you react when you were in pain?

- How did they expect you to behave when you had a minor injury?

- How did they encourage you to cope when you had severe pain?

- How did they encourage you to behave during an injection or procedure?

- When those who cared for you as a child were in pain, how did they react?

- What words did they use to describe the pain?

- How did they cope with their pain?

- Do you tend to follow their example?

Pain Experiences in Adulthood

- What painful experiences have you had as an adult (e.g., childbirth, fracture)?

- How did you express (or not express) your pain?

- Did the pain cause you fear? What were you afraid of?

- How did you cope with the pain?

- How did you want others to react while you were in pain?

Pain Experiences by Patients

- Have you ever felt uncomfortable with the way a patient was reacting (or not reacting) to pain?

- What did the patient do that concerned you?

- Why did you feel that way?

- Do you make value judgments about patients in pain who:

- Behave more stoically or expressively than you would in a similar situation?

- Ask for pain medication frequently or not often enough?

- Choose treatments you do not believe are effective or with which you are unfamiliar?

- Belong to a cultural group (e.g., ethnic, linguistic, religious, socioeconomic) different from your own?

- Do you tend to feel certain reactions to, descriptions of, or treatments for pain are "right" or "wrong?" What about these reactions makes them seem right or wrong?

FACTORS THAT CONTRIBUTE TO RACIAL AND ETHNIC DISPARITIES IN PAIN MANAGEMENT

It is clear that health disparities exist among racial and ethnic minority groups, and this is true for pain management services and medications. A large-scale national study in the United States found racial differences in the prescription of analgesics for patients with migraine, low back pain, and bone fractures [25]. Specifically, Black Americans were less likely to be prescribed analgesics for their pain compared with their white counterparts. Racial minority patients are also more likely to experience longer wait times for medication compared with white patients [20].

Analysis of a national dataset found that Black Americans were less likely to be prescribed opioids for back pain and abdominal pain compared with non-Hispanic white Americans [26]. The authors speculate that racial biases may influence prescribing behaviors. An examination of Medicaid patients who received epidural analgesia during vaginal childbirth also found statistically significant racial/ethnic differences [27]. In this study, 59.6% of the white patients received epidural analgesia, compared with 49.5% of Black Americans, 48.2% of Asians, and 35.2% of Hispanics. Even after the researchers controlled for age, urban/rural residence, and the availability of anesthesiologists, race and ethnicity still predicted epidural analgesia prescribing trends [27].

In a meta-analysis of ethnicity and pain management researchers found that professionals under-rated ethnic minority patients' levels of pain and were less likely to indicate their pain scores on their charts compared with their white counterparts [28]. In addition, Black American and Hispanic patients were less likely to have been given analgesics than white patients.

Studies have not definitively isolated the factors that contribute to these disparities. One of the challenges in understanding health disparities, and particularly pain management disparities, is the fact that racial and ethnic minority groups are heterogeneous [29,30]. Recent immigrants from Japan, for example, are going to have different cultural and social practices than from Americans with Japanese ancestry who have resided in the United States for generations [29]. However, researchers have often combined these groups, as challenges in recruitment yield small sample sizes that make it difficult for statistical analyses to be meaningful. Literature has identified a variety of reasons for these disparities stemming from several factors [31].

Barriers Related to Western Biomedical Culture

Western biomedical culture emphasizes a clear dichotomy between the mind and the body as well as what is observable (objective) and what is not (subjective) [32]. Pain is not easily measured, making its assessment and treatment a challenge in Western medicine [32]. In addition, many healthcare professionals may not be adequately trained to incorporate spirituality in the management and treatment of pain for patients who desire to incorporate a more holistic approach [33]. The Western American medical paradigm also leans toward cure rather than care [32]. Patients who present with symptoms that lead to a diagnosis for which there is a clear pathway of interventions and treatment are "favored." Because of the subjective nature of pain, healthcare professionals must often make clinical decisions in the face of a lack of absolute, clear physical evidence [34].

Societal and Institutional Barriers

Societal and institutional barriers include racism, discrimination, poverty, lack of health insurance, and deleterious environmental factors in communities [35]. For example, groups that have historically (or currently) been victims of institutional racism and discrimination are more likely to delay seeking help for pain [28]. Some studies indicate that Black American men may experience higher levels of pain intensity in part due to their experiences with different forms of racial discrimination [20]. Even today, racial and ethnic minority patients are more likely to be placed in a negative-valenced relationship [34]. In the context of pain management, healthcare providers are more likely to discount the pain due to the negative-valenced relationship triggered by racism and discrimination [34].

It has been shown that physicians tend to have less involved communication and less participatory interactions with racial minority patients and low-income patients [32]. In addition, the stereotype that certain racial minority groups come from chaotic and disorganized families and environments increases the likelihood of healthcare professionals labeling them as "difficult." Just as healthcare professionals may have preconceived notions about patients, patients may have pre-existing assumptions about the provider. For example, one study of Native American patients found that the participants tended to feel that healthcare professionals were not interested in hearing about their pain experience and did not have confidence that they would be helped [36]. Thus, a cycle of myths and stereotypes continues.

One oft-cited study found that three-quarters of pharmacies located in areas of New York City with a high proportion of racial and ethnic minority residents did not stock adequate supplies of opioid analgesics [37]. Some pharmacists attributed the low supply to lower demand, but others cited factors related to racism and discrimination. In addition, pharmacies in areas with high concentrations of racial minorities are more concerned with burglaries, additional regulations, and penalties imposed by state and federal drug-enforcement agencies than pharmacies in predominantly white neighborhoods [37].

Healthcare Professional-Related Barriers

Healthcare professional barriers may include professionals' beliefs about appropriate pain management; lack of training and knowledge about the intersection of pain and culture, race, and ethnicity; lack of culturally sensitive assessment for pain; and expectations about racial and ethnic minority pain patients based on stereotypes [38]. Consequently, practitioners may underestimate and minimize racial minority patients' pain experiences. In a qualitative study, Native American individuals described their complaints of pain being dismissed, receiving inadequate care, and neglected aftercare [39].

Studies have also shown that the language and race/ethnicity of the healthcare professional influences pain management. For example, the ratings of pain tend to be comparable when the patient and healthcare provider speak the same language. When there is a native language, pain ratings tend to diverge. When literacy and language barriers are eliminated, assessment and treatment improve, and racial and ethnic minority patients with pain fare better [40]. In addition, healthcare professionals' level of empathy appears to increase when the patient and healthcare professional share the same skin color or are of the same ethnic group [41,42].

Patient-Related Barriers

Patient barriers to effective pain management include fear and anxiety about substance misuse and addiction, cultural values such as fatalism (i.e., pain is inevitable), and ideas about being a good patient [31]. Cultural values about pain coping, definitions, expression, and experience may also be patient-related barriers. For example, those with a fatalistic perspective of pain are often stoic. A qualitative study of Somali women found that the participants felt wailing or crying about one's pain was a sign of weakness [43]. Similarly, Hispanics and Black Americans are more likely to embrace the importance of being stoic and are less likely to ask for pain medication [28]. Studies also show that Hispanic and Black American patients with cancer tend to under-report their pain for fear of being labeled as complainers or of distracting the physicians treating their illness [44]. Some patients will not ask questions for fear that would be viewed as challenging an authority figure [45]. Some ethnic/racial minority patients disclose that they avoid pain medications because they overestimate the risk dependence [45,46,47].

ALTERNATIVE REMEDIES

Practitioners should explore both traditional biomedical pain management interventions and non-traditional alternative remedies (as appropriate) when working with racial and ethnic minority patients. Complementary self-management approaches for pain can be generally classified as mind/body approaches or natural products [48]. Mind/body approaches include meditation, yoga, acupuncture, and breathing techniques. Natural products include herbs, vitamins, and topical ointments [48]. Some patients may be more receptive to traditional healing methods (e.g., herbal remedies, traditional healers) [36]. In focus groups, Native American participants reported using a range of alternative therapies for pain, including acupuncture, massage, chiropractic treatment, and guided imagery [39].

Alternative remedies for pain can be classified into five different areas, and many can be used as adjuncts to conventional therapies [49,50]:

- Alternative medications: Nonpharmacologic substances, such as those associated with homeopathic medicine, traditional Chinese medicine, and Ayurvedic medicine

- Mind-body interventions: Interventions that focus on using the mind to influence bodily symptoms, including biofeedback, meditation, music therapy, and guided imagery. Mind-body interventions help reduce pain and improve other comorbid conditions, such as depression.

- Biologically based interventions: Consumption of biologic products (e.g., herbs, vitamins, foods)

- Manipulation strategies: Adjustment of focused areas of the body (e.g., chiropractic measures, massage, acupuncture)

- Energy therapies: Balancing energy fields (e.g., electromagnetic therapy, reiki, qigong)

Some cultural groups subscribe to the hot/cold theory of disease, which argues that illnesses are the result of bodily imbalances and that foods and alternative medications are inherently "hot" or "cold." Pain is considered a "cold" disease, and some patients who adhere to traditional healing will take this into account when selecting and adhering to treatment approaches [51].

END-OF-LIFE CONSIDERATIONS

Palliative care is the noncurative care provided to patients to relieve symptoms and improve quality of life [52]. The goal of palliative care is to not only meet patients' physical needs but also address their psychologic, social, religious/spiritual, and cultural needs [18]. Even across cultures, there appear to be common denominators for effective palliative care. In an analysis of studies on palliative care in various ethnic/racial minority groups, researchers found common cultural themes that cut across all groups in the area of palliative care [19]. These included:

- Pain management

- Support to achieve closure (i.e., resolve social and emotional concerns that are hindering well-being)

- Spiritual and religious care

- Support to family and friends

- Focus on the quality of life

One concept that has been helpful in pain management at the end of life is the idea of total pain. Total pain considers the contributions of physical noxious stimuli, affect/emotional discomfort, interpersonal conflicts, and nonacceptance of one's own dying [21]. A patient's cultural perspective can influence any of these factors and/or how they are conveyed. The most important consideration at the end of life is that the patient's wishes are followed, and this almost always includes a desire for a pain-free death, regardless of background and culture.

4. CONCLUSION

Safe and effective opioid prescribing requires a balanced, patient-centered approach that recognizes both the benefits and the risks of opioid therapy. Clinicians play a critical role in ensuring that opioid analgesics are prescribed only when clinically appropriate, with careful consideration of individual patient factors, evidence-based treatment recommendations, and strategies to minimize the potential for misuse, opioid use disorder, and overdose.

Appropriate management extends beyond the initial prescription. Ongoing assessment of treatment effectiveness, functional outcomes, adverse effects, and risk factors through periodic review and monitoring enables clinicians to make informed decisions about continuing, modifying, or discontinuing opioid therapy. Consistent use of monitoring tools, documentation, and shared decision-making helps support safe, high-quality care while promoting positive patient outcomes.

Equally important is providing patients and caregivers with comprehensive education about opioid therapy. Clear communication regarding medication adherence, expected benefits and risks, safe storage, proper disposal of unused medications, and overdose prevention—including when appropriate, the use of naloxone—empowers patients to participate actively in their care and reduces the likelihood of medication-related harm.

Finally, delivering equitable pain management requires recognition that pain is a complex, multidimensional experience influenced by biological, psychological, social, and cultural factors. Awareness of how culture, race, ethnicity, language, and personal beliefs shape the perception and expression of pain can help clinicians reduce bias, improve communication, and provide more individualized, culturally responsive care.

By integrating evidence-based prescribing practices, vigilant patient monitoring, effective education, and culturally informed care into clinical practice, healthcare professionals can improve pain management while helping to address the ongoing public health challenges associated with opioid use. Continued learning and adherence to evolving clinical guidelines remain essential to optimizing patient safety and supporting responsible opioid stewardship.

Works Cited

1. Aldington D. What is the level of evidence? Indications and limitations. Presented at: The Ninth Conference of the European Pain Federation (Pain Federation EFIC); Vienna, Austria; September 2, 2015.

2. Cregg R, Russo G, Gubbay A, Branford R, Sato H. Pharmacogenetics of analgesic drugs. Br J Pain. 2013;7(4):189-208.

3. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015;8:153-158.

4. Atkinson TJ, Schatman ME, Fudin J. The damage done by the war on opioids: the pendulum has swung too far. J Pain Res. 2014;7:265-268.

5. Webster L. The pain epidemic versus the opioid crisis. P T. 2016;41(2):107-115.

6. University of Wisconsin School of Medicine and Public Health, Pain and Policy Studies Group. Achieving Balance in State Pain Policy: A Progress Report Card (CY 2013). Available at https://www.fightcancer.org/sites/default/files/PRC-2013.pdf. Last accessed July 21, 2026.

7. Katz NP, Birnbaum H, Brennan MJ. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care. 2013;19:295-302.

8. Federation of State Medical Boards. Strategies for Prescribing Opioids for the Management of Pain. Washington, DC: Federation of State Medical Boards; 2024.

9. Kaye AD, Jones MR1, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). Pain Physician. 2017;20(2S):S111-S133.

10. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/media/79776/download. Last accessed July 21, 2026.

11. American Chronic Pain Association. ACPA – Stanford Resource Guide to Chronic Pain Management: An Integrated Guide to Comprehensive Pain Therapies, 2021 Edition. Available at https://med.stanford.edu/content/dam/sm/pain/documents/ACPA-Stanford-Resource-Guide-to-Chronic-Pain-Management-2021-Edition-4-18-21-.pdf. Last accessed July 21, 2026.

12. Office of National Drug Control Policy. Proper Disposal of Prescription Drugs. Available at https://www.ncjrs.gov/ondcppubs/publications/pdf/prescrip_disposal.pdf. Last accessed July 21, 2026.

13. U.S. Food and Drug Administration. Where and How to Dispose of Unused Medicines. Available at https://www.fda.gov/consumers/consumer-updates/where-and-how-dispose-unused-medicines. Last accessed July 21, 2025.

14. U.S. Food and Drug Administration. Safe Opioid Disposal: Remove the Risk Outreach Toolkit. Available at https://www.fda.gov/drugs/ensuring-safe-use-medicine/safe-opioid-disposal-remove-risk-outreach-toolkit. Last accessed July 21, 2026.

15. American Society of Health-System Pharmacists. ASHP Policy Positions 2009-2026. Available at https://www.ashp.org/-/media/assets/policy-guidelines/docs/browse-by-document-type-policy-positions-with-rationales-pdf.pdf. Last accessed July 21, 2026.

16. Baxter J. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at https://nida.nih.gov/sites/default/files/minimizingmisuse_part1.pdf. Last accessed July 21, 2026.

17. Frohm KD, Beehler GP. Psychologists as change agents in chronic pain management practice: cultural competence in the health care system. Psychol Serv. 2010;7(3):115-125.

18. Claxton-Oldfield S, Claxton-Oldfield J, Rishchynski G. Understanding of the term "palliative care:" a Canadian survey. Am J Hosp Palliat Care. 2004;21(2):105-110.

19. Bosma H, Apland L, Kazanjian A. Cultural conceptualizations of hospice palliative care: more similarities than differences. Palliat Med. 2010;24(5):510-522.

20. Robinson-Lane SG, Booker SQ. Culturally responsive pain management for black older adults. J Gerontol Nurs. 2017;43(8):33-41.

21. Facco E, Teston I, Di Lucia D, Roncon L. Relevance of a biocultural approach in the assessment of chronic pain: a comparison between Peruvian women living in Nasca and Lima. World, Culture, Psychiatry, Research Review (WCPRR). 2013;8(1):60-70.

22. Wilner AN. Pain Management Across Cultures. Available at https://www.medscape.org/viewarticle/581930. Last accessed July 21, 2026.

23. Bates MS, Rankin-Hill L, Sanchez-Ayendez M. The effects of the cultural context of health care on treatment of and response to chronic pain and illness. Soc Sci Med. 1997;45(9):1433-1447.

24. Narayan MC. Culture's effect on pain assessment and management. Am J Nurs. 2010;110(4):38-47.

25. Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health. 2003;93(12):2067-2073.

26. Singhal A, Tien Y, Hsia RY. Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS One. 2016;11(8):1-14.

27. Rust G, Nembhard WN, Nichols, et al. Racial and ethnic disparities in the provision of epidural analgesia to Georgia Medicaid beneficiaries during labor and delivery. Am J Obstet Gynecol. 2004;191(2):456-462.

28. Cintron A, Morrison RS. Pain and ethnicity in the United States: a systematic review. J Palliat Med. 2006;9(6):1454-1473.

29. Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh. 2006;38(3):225-233.

30. Hastie BA, Riley JL 3rd, Kaplan L, et al. Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity. Pain. 2012;153(8): 1610-1619.

31. Chen CH, Tang ST, Chen CH. Meta-analysis of cultural differences in Western and Asian patient-perceived barriers to managing cancer pain. Palliat Med. 2012;26(3):206-221.

32. Crowley-Matoka M, Saha S, Dobscha SK, Burgess DJ. Problems of quality and equity in pain management: exploring the role of the biomedical culture. Pain Med. 2009;10(7):1312-1324.

33. Davidhizar R, Giger JN. A review of the literature on care of clients in pain who are culturally diverse. Int Nurs Rev. 2004;51(1): 47-55.

34. Tait RC, Chibnall JT. Racial and ethnic disparities in the evaluation and treatment of pain: psychological perspectives. Prof Psychol Res Pr. 2005;36(6):595-601.

35. Mossey JM. Defining racial and ethnic disparities in pain management. Clin Orthop Relat Res. 2011;469(7):1859-1870.

36. Jimenez N, Garroutte E, Kundu A, Morales L, Buchwald D. A review of the experience, epidemiology, and management of pain among American Indian, Alaska Native, and aboriginal Canadian peoples. J Pain. 2011;12(5):511-522.

37. Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL. "We don't carry that:" failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Eng J Med. 2000;6(342):1023-1026.

38. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10(12): 1187-1204.

39. Haozous EA, Doorenbos AZ, Stoner S. Pain management experiences and the acceptability of cognitive behavioral strategies among American Indians and Alaska Natives. J Transcult Nurs. 2016;27(3):233-240.

40. Pillay T, van Zyl HA, Blackbeard D. Chronic pain perception and cultural experience. Procedia Soc Behav Sci. 2014;113:151-160.

41. Campbell CM, Edwards RR. Ethnic differences in pain and pain management. Pain Manag. 2012;2(3):219-230.

42. Gagnon CM, Matsuura JT, Smith CC, Stanos SP. Ethnicity and interdisciplinary pain treatment. Pain Pract. 2014;14(6):532-540.

43. Finnström B, Söderhamn O. Conceptions of pain among Somali women. J Adv Nurs. 2006;54(4):418-425.

44. Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. 2003;4(3):277-294.

45. Tung WC, Li Z. Pain beliefs and behaviors among Chinese. Home Health Care Management & Practice. 2015;27(2):95-97.

46. Davidhizar RE, Hart AN. Pain management: delivering culturally appropriate care. Healthcare Traveler. 2005;12(12):32-41.

47. Booker SQ. African Americans' perceptions of pain and pain management: a systematic review. J Transcult Nurs. 2016;27(1):73-80.

48. Eaton LH, Meins AR, Rue T, Doorenbos AZ, Langford DJ, Tauben DJ. Use of self-management interventions for chronic pain management: a comparison between rural and nonrural residents. Pain Manag Nurs. 2018;19(1):8-13.

49. Majeed MH, Ali AA, Sudak DM. Review article: mindfulness-based interventions for chronic pain: evidence and applications. Asian J Psychiatr. 2018;32:79-83.

50. Lin YC, Lee ACC, Kemper KJ, Berde CB. Use of complementary and alternative medicine in pediatric pain management service: a survey. Pain Med. 2005;6(6):452-458.

51. Hollingshead NA, Ashburn-Nardo L, Stewart JC, Hirsh AT. Critical review: the pain experience of Hispanic Americans: a critical literature review and conceptual model. J Pain. 2016;17(5):513-528.

52. Chater K, Tsai CT. Palliative care in a multicultural society: a challenge for Western ethics. Aust J Adv Nurs. 2008;26(2):95-100.

53. U.S. Food and Drug Administration. Drug Disposal: Drug Take-Back Options. Available at https://www.fda.gov/drugs/disposal-unused-medicines-what-you-should-know/drug-disposal-drug-take-back-options. Last accessed July 21, 2026.

54. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR. 2022;71(RR3):1-95.

Evidence-Based Practice Recommendations Citations

1. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR. 2022;71(RR3):1-95. Available at https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm. Last accessed July 24, 2026.